Thompson Mark G, Naleway Allison, Fry Alicia M, Ball Sarah, Spencer Sarah M, Reynolds Sue, Bozeman Sam, Levine Min, Katz Jacqueline M, Gaglani Manjusha
Epidemiology and Prevention Branch, Influenza Division/NCIRD/CDC, Atlanta, GA 30333.
The Center for Health Research, Kaiser Permanente Northwest, Portland, OR 97227.
Vaccine. 2016 Feb 10;34(7):981-8. doi: 10.1016/j.vaccine.2015.10.119.
Recently, lower estimates of influenza vaccine effectiveness (VE) against A(H3N2) virus illness among those vaccinated during the previous season or multiple seasons have been reported; however, it is unclear whether these effects are due to differences in immunogenicity.
We performed hemagglutination inhibition antibody (HI) assays on serum collected at preseason, ∼ 30 days post-vaccination, and postseason from a prospective cohort of healthcare personnel (HCP). Eligible participants had medical and vaccination records for at least four years (since July, 2006), including 578 HCP who received 2010-11 trivalent inactivated influenza vaccine [IIV3, containing A/Perth/16/2009-like A(H3N2)] and 209 HCP who declined vaccination. Estimates of the percentage with high titers (≥ 40 and>100) and geometric mean fold change ratios (GMRs) to A/Perth/16/2009-like virus by number of prior vaccinations were adjusted for age, sex, race, education, household size, hospital care responsibilities, and study site.
Post-vaccination GMRs were inversely associated with the number of prior vaccinations, increasing from 2.3 among those with 4 prior vaccinations to 6.2 among HCP with zero prior vaccinations (F[4,567]=9.97, p<.0005). Thirty-two percent of HCP with 1 prior vaccination achieved titers >100 compared to only 11% of HCP with 4 prior vaccinations (adjusted odds ratio=6.8, 95% CI=3.1 - 15.3).
Our findings point to an exposure-response association between repeated IIV3 vaccination and HI for A(H3N2) and are consistent with recent VE observations. Ultimately, better vaccines and vaccine strategies may be needed in order to optimize immunogenicity and VE for HCP and other repeated vaccinees.
最近有报道称,对上一季或多个季节接种疫苗者中流感疫苗对甲型(H3N2)病毒疾病的有效性(VE)估计较低;然而,尚不清楚这些影响是否归因于免疫原性差异。
我们对一组前瞻性医护人员(HCP)在季前、接种疫苗后约30天和季后采集的血清进行了血凝抑制抗体(HI)检测。符合条件的参与者有至少四年(自2006年7月起)的医疗和疫苗接种记录,其中包括578名接种2010 - 11年三价灭活流感疫苗[IIV3,含A/珀斯/16/2009样甲型(H3N2)]的HCP和209名拒绝接种疫苗的HCP。根据年龄、性别、种族、教育程度、家庭规模、医院护理职责和研究地点,对按既往接种次数划分的高滴度(≥40和>100)百分比估计值以及对A/珀斯/16/2009样病毒的几何平均倍数变化率(GMR)进行了调整。
接种疫苗后的GMR与既往接种次数呈负相关,既往接种4次者的GMR为2.3,而既往无接种史的HCP的GMR为6.2(F[4,567]=9.97,p<.0005)。既往接种1次的HCP中有32%的人滴度>100,而既往接种4次的HCP中只有11%(调整后的优势比=6.8,95%置信区间=3.1 - 15.3)。
我们的研究结果表明,重复接种IIV3疫苗与针对甲型(H3N2)的HI之间存在暴露 - 反应关联,并且与最近的VE观察结果一致。最终,可能需要更好的疫苗和疫苗策略,以优化医护人员和其他重复接种疫苗者的免疫原性和VE。